Heparin

Generic Name: Heparin

Brand Names: Heparin Leo

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: T2410KM04A

Background: Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...

Indication: Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...

Associated Conditions: Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein

Associated Therapies: Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Clinical Trials

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Phase 3

Terminated

Conditions: Renal Insufficiency

Interventions: Drug: Apixaban
Drug: Heparin
Drug: VKA
Drug: Rivaroxaban

First Posted Date: 2016-01-26

Last Posted Date: 2022-10-19

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 203

Registration Number: NCT02664155

Locations: 🇫🇷
CHU Toulouse, Toulouse 9, France
🇫🇷
CH de Valenciennes, Valenciennes, France
🇫🇷
CH ARRAS, Arras, Boulevard Georges Besnier, France

and more 28 locations

Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment

Completed

Conditions: Lipoprotein Lipase Deficiency

First Posted Date: 2016-01-14

Last Posted Date: 2019-07-11

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 12

Registration Number: NCT02656095

Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation

Phase 3

Recruiting

Conditions: Disseminated Intravascular Coagulation
Sepsis

Interventions: Drug: Heparin Sodium
Drug: Saline

First Posted Date: 2016-01-13

Last Posted Date: 2023-11-18

Lead Sponsor: China Medical University, China

Target Recruit Count: 600

Registration Number: NCT02654561

Locations: 🇨🇳
The fist Affiliated Hospital Harbin Medical University, Haerbin, Heilongjiang, China
🇨🇳
Xiangya Third Hospital of Central South University, Changsha, Hunan, China
🇨🇳
First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

and more 14 locations

Reprometabolic Syndrome Mediates Subfertility in Obesity

Not Applicable

Completed

Conditions: Obesity
Infertility
Hypogonadotropic Hypogonadotropism
Hyperinsulinemia

Interventions: Drug: Insulin
Drug: Intralipid
Drug: Dextrose
Drug: GnRH
Drug: Heparin
Procedure: Hyperinsulinemic Euglycemic Clamp

First Posted Date: 2016-01-12

Last Posted Date: 2024-11-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 84

Registration Number: NCT02653092

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Phase 3

Completed

Conditions: Kidney Failure, Chronic
Catheter-Related Infections

Interventions: Drug: Neutrolin
Drug: Heparin

First Posted Date: 2016-01-11

Last Posted Date: 2021-08-31

Lead Sponsor: CorMedix

Target Recruit Count: 806

Registration Number: NCT02651428

Locations: 🇺🇸
Diagnostic Clinic of Houston, Houston, Texas, United States
🇺🇸
Riverside Nephrology Physicians/Van Buren Dialysis center, Riverside, California, United States
🇺🇸
North America Research Institute, San Dimas, California, United States

and more 2 locations

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Phase 2

Terminated

Conditions: Bladder Pain Syndrome
Interstitial Cystitis

Interventions: Drug: Lidocaine
Drug: URG101
Drug: Placebo
Drug: Heparin

First Posted Date: 2015-10-29

Last Posted Date: 2020-08-26

Lead Sponsor: Urigen

Target Recruit Count: 92

Registration Number: NCT02591199

Locations: 🇺🇸
IC Study, LLC, Escondido, California, United States
🇺🇸
Rutgers Women's Health Clinic, New Brunswick, New Jersey, United States
🇺🇸
University of California San Diego, San Diego, California, United States

and more 8 locations